83 related articles for article (PubMed ID: 31604579)
1. Corrigendum to "IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas." [Cancer Lett. 458C (2019) 29-38].
Mihajluk K; Simms C; Reay M; Madureira PA; Howarth A; Murray P; Nasser S; Duckworth CA; Pritchard DM; Pilkington GJ; Hill R
Cancer Lett; 2020 Jan; 469():524-525. PubMed ID: 31604579
[No Abstract] [Full Text] [Related]
2. Retraction notice to " IP1867B suppresses the Insulin-like Growth Factor 1 Receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas" [Canc. Lett., 458 (2019) pages 29-38].
Mihajluk K; Simms C; Reay M; Madureira PA; Howarth A; Murray P; Nasser S; Duckworth CA; Pritchard DM; Pilkington GJ; Hill R
Cancer Lett; 2021 Jun; 507():39. PubMed ID: 33743517
[No Abstract] [Full Text] [Related]
3. RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Mihajluk K; Simms C; Reay M; Madureira PA; Howarth A; Murray P; Nasser S; Duckworth CA; Pritchard DM; Pilkington GJ; Hill R
Cancer Lett; 2019 Aug; 458():29-38. PubMed ID: 31129148
[TBL] [Abstract][Full Text] [Related]
4. Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Isoyama S; Kajiwara G; Tamaki N; Okamura M; Yoshimi H; Nakamura N; Kawamura K; Nishimura Y; Namatame N; Yamori T; Dan S
Cancer Sci; 2015 Feb; 106(2):171-8. PubMed ID: 25483727
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.
Liu TC; Hsieh MJ; Liu MC; Chiang WL; Tsao TC; Yang SF
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213344
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
8. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
9. TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells.
Schedlich LJ; Yenson VM; Baxter RC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):56-64. PubMed ID: 23831640
[TBL] [Abstract][Full Text] [Related]
10. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Suda K; Mizuuchi H; Sato K; Takemoto T; Iwasaki T; Mitsudomi T
Int J Cancer; 2014 Aug; 135(4):1002-6. PubMed ID: 24458568
[TBL] [Abstract][Full Text] [Related]
12. Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1.
Ueda S; Tsuda H; Sato K; Takeuchi H; Shigekawa T; Matsubara O; Hiraide H; Mochizuki H
Cancer Sci; 2006 Jul; 97(7):597-604. PubMed ID: 16827799
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE.
Alkhayyal N; Talaat I; Vinodnadat A; Maghazachi A; Abusnana S; Syrjänen K; Bendardaf R
Anticancer Res; 2020 Mar; 40(3):1555-1561. PubMed ID: 32132057
[TBL] [Abstract][Full Text] [Related]
14. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
[TBL] [Abstract][Full Text] [Related]
15. The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study.
Jaillardon L; Abadie J; Godard T; Campone M; Loussouarn D; Siliart B; Nguyen F
BMC Cancer; 2015 Oct; 15():664. PubMed ID: 26449867
[TBL] [Abstract][Full Text] [Related]
16. Both epidermal growth factor and insulin-like growth factor receptors are dispensable for structural intestinal adaptation.
Sun RC; Diaz-Miron JL; Choi PM; Sommovilla J; Guo J; Erwin CR; Warner BW
J Pediatr Surg; 2015 Jun; 50(6):943-7. PubMed ID: 25818318
[TBL] [Abstract][Full Text] [Related]
17. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors.
Evdokimova V; Tognon CE; Benatar T; Yang W; Krutikov K; Pollak M; Sorensen PH; Seth A
Sci Signal; 2012 Dec; 5(255):ra92. PubMed ID: 23250396
[TBL] [Abstract][Full Text] [Related]
18. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.
Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L
Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918
[No Abstract] [Full Text] [Related]
19. Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.
Björner S; Rosendahl AH; Simonsson M; Markkula A; Jirström K; Borgquist S; Rose C; Ingvar C; Jernström H
Oncotarget; 2017 Feb; 8(6):9093-9107. PubMed ID: 28030849
[TBL] [Abstract][Full Text] [Related]
20. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
Nurwidya F; Takahashi F; Kobayashi I; Murakami A; Kato M; Minakata K; Nara T; Hashimoto M; Yagishita S; Baskoro H; Hidayat M; Shimada N; Takahashi K
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):332-8. PubMed ID: 25446090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
